Mechanisms, Risk Factors, and Clinical Impact of Hyperkalemia

Primary Pathophysiologic Mechanisms

Hyperkalemia arises through three core mechanisms: (1) excess potassium intake, (2) reduced renal or gastrointestinal potassium excretion (the most frequent mechanism), and (3) transcellular shift of potassium from the intracellular to the extracellular compartment. 1

Reduced Potassium Excretion

Impaired potassium excretion is the predominant mechanism in clinical practice, especially among individuals with renal impairment. 1
The prevalence of hyperkalemia rises sharply with worsening kidney function, affecting up to 73 % of patients with advanced chronic kidney disease and up to 40 % of patients with chronic heart failure. 1, 2
Medications that diminish potassium excretion include:
- Renin‑angiotensin‑aldosterone system inhibitors (ACE inhibitors, ARBs, mineralocorticoid receptor antagonists, direct renin inhibitors, sacubitril/valsartan). 3
- Beta‑blockers. 4
- Non‑steroidal anti‑inflammatory drugs. 4
- Immunosuppressants such as cyclosporine, tacrolimus, and other calcineurin inhibitors. 4
- Certain antimicrobials (e.g., trimethoprim‑sulfamethoxazole, pentamidine, penicillin G). 4
- Other agents (heparin, digitalis, mannitol). 4

Increased Potassium Intake

Excessive potassium intake alone is an uncommon sole cause, but it becomes clinically relevant when excretory capacity is compromised. 1
The most severe hyperkalemia cases occur after large intravenous potassium administrations to patients with renal insufficiency. 4
Certain herbal and dietary supplements (e.g., alfalfa, dandelion, hawthorn berry, horsetail, nettle, noni juice, Siberian ginseng) can contribute to excess potassium load. 4

Transcellular Potassium Shift

Potassium normally resides 98 % intracellularly; a shift to the extracellular space (normally 2 %) can raise serum levels. 2, 5
A clinically significant shift generally requires concurrent impairment of potassium excretion. 1
Identified precipitants of the shift include:
- Massive cell lysis (rhabdomyolysis, tumor‑lysis syndrome, hemolysis). 6
- Acute pancreatitis. 4
- Acute hepatic failure. 4

High‑Risk Patient Populations

Patients with multiple comorbid conditions are at heightened risk for hyperkalemia. 6
Reported prevalence ranges from 2–4 % in the general community to 10–55 % among hospitalized individuals, with both prevalence and recurrence climbing as the number and severity of comorbidities increase. 1, 2

Pseudo‑hyperkalemia

Pseudo‑hyperkalemia denotes a falsely elevated serum potassium result caused by potassium release from blood cells or tissue during specimen collection. 1, 2, 7
When suspected, repeat measurement using properly drawn venous or arterial samples is recommended. 1
In cases of hemolysis, clinicians should determine whether the hemolysis occurred in‑tube or in‑the patient. 1

Clinical Consequences

Hyperkalemia is frequently iatrogenic, driven by concurrent use of drugs and nutritional/herbal supplements. 1, 2
Inadequate monitoring of at‑risk patients leads to higher hospitalization rates and increased mortality. 1
The condition is associated with higher all‑cause mortality, greater cardiovascular mortality, and accelerated progression to end‑stage renal disease. 3

Management Implications for RAAS Inhibitors

RAAS inhibitor therapy, while beneficial for cardiovascular outcomes, commonly induces hyperkalemia and is often down‑titrated or discontinued despite its mortality‑reducing effects. 2, 3
Reducing or stopping RAAS inhibitors is linked to increased overall mortality, more frequent heart‑failure admissions, and faster progression to end‑stage kidney disease. 3

Endocrine Causes of Non‑Renal Hyperkalemia

Addison Disease

Addison disease (primary adrenal insufficiency) causes chronic hyperkalemia because aldosterone deficiency diminishes renal potassium excretion, making the condition a non‑reversible endocrine contributor to recurrent hyperkalemia in affected patients. 8

Evidence‑Based Factors Contributing to Hyperkalemia

Primary Causes (Cited Evidence)

Renal failure and concomitant drug therapy are identified as the most common overall causes of hyperkalemia in patients. 9
Massive cellular destruction (e.g., rhabdomyolysis, tumor‑lysis syndrome, hemolysis), acute pancreatitis, and acute hepatic failure are recognized precipitating events for trans‑cellular potassium shifts that can trigger hyperkalemia. 9
Administration of large intravenous potassium loads to individuals with impaired renal function frequently leads to the most severe hyperkalemic presentations. 9

Clinical Context and Risk Amplifiers

In a large retrospective analysis, acute kidney injury was present in all cases of cardiac arrest that were directly attributed to hyperkalemia, underscoring AKI as a critical risk factor. 9

Pseudohyperkalemia (Laboratory Artifact)

Pseudohyperkalemia may arise from platelet release during clot formation; consequently, plasma potassium concentrations are typically 0.1–0.4 mEq/L lower than serum values. 10

Hyperkalemia in Older Adults: Renal, Medication, Dietary, and Endocrine Contributors

Renal Function and Hyperkalemia Risk

In patients ≥ 65 years, a serum creatinine of ≈ 1.1 mg/dL often corresponds to an estimated GFR of 45–60 mL/min/1.73 m²; because low muscle mass blunts creatinine rise, the true renal impairment may be underestimated. American Heart Association data support this interpretation. 11
The likelihood of hyperkalemia rises progressively when eGFR falls below 60 mL/min/1.73 m², even with modest potassium elevations. Evidence from the Mayo Clinic cohort demonstrates this dose‑response relationship. 12

Medication‑Induced Hyperkalemia (Non‑RAAS Inhibitors)

Non‑steroidal anti‑inflammatory drugs (e.g., ibuprofen, naproxen) impair renal potassium excretion and increase hyperkalemia risk, especially in the elderly. European Society of Cardiology studies confirm this association. 13
Potassium‑sparing diuretics—including spironolactone, eplerenone, amiloride, and triamterene—can precipitate hyperkalemia by directly reducing urinary potassium loss. Findings are reported by the American Heart Association and European Society of Cardiology. [11] [14]
Calcineurin inhibitors (cyclosporine, tacrolimus) are linked to elevated serum potassium through reduced distal tubular secretion; the Mayo Clinic analysis quantifies this effect. 12
Unfractionated or low‑molecular‑weight heparin may cause hyperkalemia by decreasing aldosterone synthesis; this mechanism is described in the Mayo Clinic literature. 12
Oral potassium supplements, when taken in the setting of impaired renal clearance, can push serum potassium into the hyperkalemic range. Evidence from the American Heart Association and European Society of Cardiology supports this risk. 11

Dietary Potassium Load in the Context of Reduced GFR

Consumption of high‑potassium foods (e.g., bananas, potatoes, tomatoes) becomes clinically significant for patients with eGFR < 60 mL/min/1.73 m², as the kidneys’ capacity to excrete excess potassium is compromised. This relationship is documented by the Mayo Clinic. 12

Endocrine Causes

Primary adrenal insufficiency (Addison disease) leads to chronic hyperkalemia via aldosterone deficiency, which diminishes renal potassium excretion. When hyperkalemia is unexplained, screening for this condition is warranted. European Society of Cardiology data highlight the association. 13
Concurrent hyponatremia often accompanies Addison disease–related hyperkalemia, providing an additional diagnostic clue. Evidence from the European Society of Cardiology supports this finding. 13
Symptoms such as hypotension and fatigue may accompany adrenal insufficiency‑related hyperkalemia; the European Society of Cardiology reports these clinical features. 14

Diagnostic Recommendations with Evidentiary Support

Estimate GFR using the CKD‑EPI equation rather than relying on serum creatinine alone in older adults, as this method more accurately reflects true renal function. This recommendation is based on American Heart Association research. 11
Conduct a thorough review of dietary potassium intake (including high‑potassium foods and supplements) when eGFR is reduced, as dietary excess can exacerbate hyperkalemia. Supported by Mayo Clinic findings. 12

All facts are derived from peer‑reviewed sources and are presented with their corresponding citation identifiers.

Renal Potassium Handling

Primary Role of the Kidneys

The kidneys constitute the main pathway for potassium elimination, and overall potassium homeostasis is largely dependent on renal function. 15

High‑Risk Populations for Hyperkalemia

Chronic Kidney Disease Combined with Diabetes or Heart Failure

Patients with chronic kidney disease (CKD) who also have diabetes mellitus or heart failure exhibit a markedly increased risk of developing hyperkalemia. [16][17]